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A B S T R A C T
Purpose
Tasquinimod, a novel oral therapy targeting the tumor microenvironment, signiﬁcantly improved
progression-free survival (PFS) in a randomized, placebo-controlled phase II trial in men with
metastatic castration-resistant prostate cancer (mCRPC). This phase III study was conducted to
conﬁrm the phase II results and to detect an overall survival (OS) beneﬁt.
Patients and Methods
Men with chemotherapy-naı¨ve mCRPC and evidence of bone metastases were assigned (2:1) to
receive tasquinimod once per day or placebo until progression or toxicity. The primary end point was
radiographic PFS (rPFS; time from random assignment to radiologic progression or death) per
Prostate Cancer Working Group 2 criteria and RECIST 1.1. The study had 99.9% power to detect an
rPFS hazard ratio (HR) of 0.6 with a two-sided alpha error of .05 and 80% power to detect a target HR
of 0.8 for OS, the key secondary end point.
Results
In all, 1,245 patients were randomly assigned to either tasquinimod (n = 832) or placebo (n = 413)
betweenMarch 2011 andDecember 2012 at 241 sites in 37 countries. Baseline characteristics were
balanced between groups:median age, 71 years; Karnofsky performance status$ 90%, 77.3%; and
visceral metastases, 21.1%. Estimatedmedian rPFS by central reviewwas 7.0 months (95%CI, 5.8
to 8.2months) with tasquinimod and 4.4months (95%CI, 3.5 to 5.5months) with placebo (HR, 0.64;
95% CI, 0.54 to 0.75; P , .001). Median OS was 21.3 months (95% CI, 19.5 to 23.0 months) with
tasquinimod and 24.0months (95%CI, 21.4 to 26.9months) with placebo (HR, 1.10; 95%CI, 0.94 to
1.28; P = .25). Grade $ 3 adverse events were more frequent with tasquinimod (42.8% v 33.6%),
the most common being anemia, fatigue, and cancer pain.
Conclusion
In chemotherapy-naı¨ve men with mCRPC, tasquinimod signiﬁcantly improved rPFS compared with
placebo. However, no OS beneﬁt was observed.
J Clin Oncol 34:2636-2643. © 2016 by American Society of Clinical Oncology
INTRODUCTION
Treatment options for metastatic castration-
resistant prostate cancer (mCRPC) have ex-
panded with the introduction of several new
agents that delay disease progression and
improve overall survival (OS). These include
second-generation androgen-directed therapies,
radium-223, sipuleucel-T, and the taxanes cab-
azitaxel and docetaxel. Despite these advances,
mCRPC remains incurable, and survival beneﬁts
typically achieved with newer agents are modest
while resistance remains common.1-7 New agents
with alternative mechanisms of action that fur-
ther improve survival while minimizing toxicity
are needed.
The tumor microenvironment is increasingly
recognized as playing a major role in the formation
and growth of metastases.8 In addition, the host
microenvironment has been shown to promote
prostate cancer invasion, systemic spread, bone
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colonization, and osteoblastic metastasis.9 Drugs that target the
tumor microenvironment therefore offer a potentially new ap-
proach in the treatment of advanced prostate cancer.10 Tasqui-
nimod (ABR-215050; Active Biotech, Lund, Sweden) is an oral
immunotherapy with demonstrated effects on the tumor micro-
environment that counteract tumor growth.11,12 One molecular
target of tasquinimod is the immunomodulatory protein S100A9,
which plays a role in the accumulation and function of innate
immune cells, speciﬁcally regulatory myeloid cells.11-13 Targeting
regulatory myeloid cells within the tumor microenvironment leads
to decreased immune suppression and angiogenesis and pre-
vention of metastasis development. Tasquinimod may also reduce
angiogenesis by downregulation of HIF1-controlled genes via
interaction with histone deacetylases.14
In a randomized, placebo-controlled phase II study in men
with mCRPC, tasquinimod signiﬁcantly improved progression-
free survival (PFS; median, 7.6 v 3.3 months; hazard ratio [HR],
0.57; P , .01).15 In long-term follow-up, multivariate analysis
indicated that the PFS improvement may be associated with im-
proved OS, particularly in patients with bone metastases.16 The
objective of this phase III study was to conﬁrm the beneﬁt of
tasquinimod in delaying disease progression and improving OS in
men with mCRPC.
PATIENTS AND METHODS
Patients
Eligible patients had histologically conﬁrmed prostate adenocarci-
noma with evidence of bone metastases, serum testosterone # 50 ng/dL,
disease progression (increasing serum prostate-speciﬁc antigen [PSA] as
deﬁned by the Prostate Cancer Working Group 2 [PCWG2],17 progression
of soft tissue metastasis, or bone disease progression), and Karnofsky
performance status $ 70%. Concurrent use of luteinizing hormone-
releasing hormone agonists or antagonists and bone agents (denosumab
or bisphosphonates) was permitted.
No cytotoxic chemotherapy within 2 years or previous anticancer
therapy within 4 weeks (2 weeks for sipuleucel-T) of random assignment
was allowed. Prior enzalutamide or abiraterone was permitted. Other
exclusion criteria included presence of prostate cancer pain requiring
opiate analgesics, systemic exposure to ketoconazole, and ongoing cor-
ticosteroid treatment equivalent to a prednisolone or prednisone dose
of . 10 mg/day.
Study Design
This multinational, randomized, double-blind, placebo-controlled
phase III study was conducted at 241 sites in 37 countries (Appendix Table
A1, online only). Patients were randomly assigned in a 2:1 ratio to receive
tasquinimod or placebo by using an interactive voice response system.
Random assignment was stratiﬁed by Karnofsky performance status
($ 90% v , 90%), presence or absence of visceral disease (all metastatic
soft tissue except lymph nodes and local recurrence), and geographic
region (North America, Europe, the Middle East, Africa, Asia-Paciﬁc, and
Latin America). Tasquinimod or placebo was administered orally at
a starting dose of 0.25 mg/day for at least 2 weeks.18 If tolerability was
established, the dose was escalated to 0.5 mg/day for 2 weeks and then to
1 mg/day. Patients unable to tolerate the escalated doses could continue in
the study at their maximum tolerated dose. Treatment continued until
symptomatic disease progressed so that it required alternative antitumor
therapy or until poor tolerability occurred. After the end of treatment,
patients continued follow-up with visits every 3 months until death or until
727 patients had reached the survival end point.
The study was approved by the institutional review boards or ethics
committees at each participating center and was conducted in accordance
with the Declaration of Helsinki. All patients provided written informed
consent before study entry.
End Points
The primary end point was radiographic PFS (rPFS), the time from
random assignment to radiologic progression or death, whatever the
cause. Radiographic progression was deﬁned as soft tissue progression
(RECIST 1.1),19 bone progression detected with conﬁrmatory bone scans
(PCWG2),7 or radiographically conﬁrmed spinal cord compression or
fracture as a result of malignant progression. Soft tissue lesions were
evaluated by computed tomography or magnetic resonance imaging
scans by the investigator. All scans underwent independent central re-
view, with reviewers blinded to study treatment and investigator
assessments.
The key secondary end point was OS, deﬁned as time from random
assignment to death. Other prespeciﬁed secondary end points included
time to radiologic progression, time to symptomatic progression, time to
PSA progression, time to initiation of further cytotoxic therapy, time to
opiate use, and time to deterioration of quality-of-life (QoL) measure
(Functional Assessment of Cancer Therapy-Prostate [FACT-P]). Safety was
assessed on the basis of physical examination, vital signs measurements,
clinical laboratory analyses, and adverse events (AEs; coded using Medical
Dictionary for Regulatory Activities [MedDRA]; graded using Common
Terminology Criteria for Adverse Events [CTCAE] version 4.0).
Statistical Analysis
The planned sample size of 1,200 patients (800 in the tasquinimod
arm and 400 in the placebo arm) provided 99.9% power at a two-sided
signiﬁcance level of 0.05 to detect an HR of 0.6 for the primary end point of
rPFS, corresponding to an increase in median PFS from 3.4 to 5.7 months.
The study was also designed to detect an HR of 0.8 for the key secondary
end point of OS, corresponding to an increase in median OS from 22 to
27.5 months. Specifying a two-sided signiﬁcance level of 0.05, the study
had 80% power to detect the OS difference after 727 deaths had been
observed. The OS end point comparisons incorporated group sequential
design involving two interim analyses (at 473 and 582 events) and a ﬁnal
analysis at 727 events using O’Brien-Fleming stopping boundaries20: ﬁrst
interim analysis, P # .0109; second interim analysis, P # .0212; and ﬁnal
analysis, P # .0422. rPFS was analyzed at the ﬁrst planned interim
analysis for OS (after 473 events). If the comparison of rPFS reached
statistical signiﬁcance (P # .05), the ﬁrst comparison of OS was per-
formed; however, the results were not reported until the ﬁnal analysis.
A stratiﬁed log-rank test by factors at random assignment was used to
compare rPFS, OS, and the time-to-event secondary end points for tas-
quinimod versus placebo (analysis of PSA doubling time was not strati-
ﬁed). To describe time-to-event variables, Kaplan-Meier curves and life
tables by treatment group were generated, and CIs were calculated.21
Patients who did not experience an event were censored at the date of their
last adequate assessment, previous assessment, last visit, or death,
depending on the end point and analysis. Treatment effect was estimated
by calculating the HR and its 95% CI from a Cox proportional hazards
model stratiﬁed by factors at random assignment. For rPFS and OS, Cox
proportional hazards models were performed for predeﬁned subgroups
and multivariate analyses. In the latter analyses, after testing each pre-
speciﬁed prognostic factor with a univariate analysis, a backward selection
approach was used. Treatment was always included in the models.
All efﬁcacy end points were analyzed by planned treatment in the
intent-to-treat population (all randomly assigned patients, regardless of
whether any study treatment dosing was completed). The safety analysis
population comprised all patients who received at least one dose of study
treatment. Safety was analyzed according to treatment received. All sta-
tistical analyses were performed by using SAS version 9.2 (SAS Institute,
Cary, NC).
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RESULTS
Patient Disposition
Of 1,645 patients screened, 1,245 were randomly assigned to
receive tasquinimod (n = 832) or placebo (n = 413) betweenMarch
29, 2011, and December 7, 2012 (Appendix Table A1). Two patients
from each group did not receive treatment after random assign-
ment (Fig 1). Baseline characteristics were generally well balanced
between the groups (Table 1). A greater proportion of patients in
the tasquinimod group had higher levels of baseline tumor pain
(Visual Analog Scale . 4: 18.6% v 14.5%). Median time since
diagnosis was shorter in the tasquinimod group than in the placebo
group (45.7 v 57.7 months).
At ﬁnal analysis (cutoff date: February 13, 2015), median
follow-up was 30.0 months in the tasquinimod arm and
30.7 months in the placebo arm, and 96.1% of patients had dis-
continued treatment. The most common reasons for discontin-
uation (tasquinimod v placebo) were radiographic progression
(23.8% v 36.5%), symptomatic progression requiring new anti-
cancer therapy (21.3% v 18.8%), and poor tolerability or AEs
(17.9% v 8.8%; Fig 1).
Efficacy
The ﬁnal analysis of the primary end point of rPFS was
performed at the time of the ﬁrst interim analysis of OS. Radio-
graphic progression by central review, or death, occurred in 396
patients (48%) in the tasquinimod group and in 258 patients
(62%) in the placebo group. Estimated median rPFS was
7.0 months (95% CI, 5.8 to 8.2 months) for tasquinimod and
4.4 months (95% CI, 3.5 to 5.5 months) months for placebo,
corresponding to a 36% reduction in the risk of radiographic
progression or death with tasquinimod versus placebo (HR, 0.64;
95% CI, 0.54 to 0.75; P, .001; Fig 2A). Similar results were seen in
the assessment by local review: estimated median rPFS was
5.7 months (95% CI, 5.5 to 6.2 months) and 4.1 months (95% CI,
3.1 to 5.1 months), respectively (HR 0.69; 95% CI, 0.60 to 0.80;
P , .001).
OS results were not signiﬁcant at either of the two interim
analyses and, because no safety concerns were raised, the Data
and Safety Monitoring Board recommended continuation of
the study according to the protocol. At ﬁnal analysis of OS,
492 deaths (59.1%) had occurred in the tasquinimod group and
238 deaths (57.6%) had occurred in the placebo group. Tas-
quinimod did not improve OS compared with placebo (median
OS, 21.3 months [95% CI, 19.5 to 23.0 months] with tasqui-
nimod and 24.0 months [95% CI, 21.4 to 26.9 months] with
placebo; HR, 1.10; 95% CI, 0.94 to 1.28; P = .25; Fig 2B). The
rPFS and OS results were consistent when examined across
predeﬁned patient subgroups without evidence of signiﬁcant
heterogeneity (Fig 3).
In general, secondary end points that favored tasquinimod
over placebo included the radiographic- and PSA-based outcomes
(Table 2 and Appendix Table A2, online only). In contrast,
symptomatically assessed end points, such as time to symptomatic
progression, time to opiate use, and deterioration in QoL, favored
placebo. Time to initiation of salvage therapy was longer with
tasquinimod than with placebo (11.4 v 8.1 months; P = .001), as
was time to initiation of further cytotoxic therapy (25.8 v
16.0 months; P = .021).
One quarter of patients (315 [25.3%] of 1,245) had un-
dergone orchiectomy, and most patients (1,178 [94.6%] of 1,245)
had received hormonal therapy pre-enrollment (mostly bicalu-
tamide, ﬂutamide, and luteinizing hormone-releasing hormone
analogs). In contrast, only a few patients had received prior
abiraterone (ﬁve patients [0.6%] in the tasquinimod group v
seven patients [1.7%] in the placebo group) or enzalutamide
(zero v one [0.2%]). These treatments were more commonly
Randomly assigned to TASQ or placebo
(2:1 ratio)
(N = 1,245)
Randomly assigned 
TASQ
(n = 832; 100%)
Continued study drug
at data cutoff
(n = 11; 2.7%)
Continued study drug
at data cutoff
(n = 33; 4.0%)
TASQ treated
(n = 830; 99.8%)
Placebo treated
(n = 411; 99.5%)
Randomly assigned 
placebo
(n = 413; 100%)
Radiological progression (23.8%)
Symptomatic progression (21.3%)
Poor tolerability (9.5%)
Adverse event (8.4%)
Patient withdrew consent (7.0%)
Discontinued by cutoff
(n = 797; 95.8%)
Radiological progression (36.5%)
Symptomatic progression (18.8%)
Poor tolerability (3.5%)
Adverse event (5.3%)
Patient withdrew consent (4.5%)
Discontinued by cutoff
(n = 400; 96.9%)
Fig 1. CONSORTdiagram.TASQ, tasquinimod.
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available during the follow-up period after withdrawal from study
treatment and were used more in the placebo group (abiraterone,
209 [25%] v 127 [31%]; enzalutamide, 66 [8%] v 48 [12%]).
More than one third of patients received docetaxel after the study
(281 [34%] v 166 [40%]).
Drug Exposure and Safety
Overall median treatment duration was 137 days (range, 1 to
1,377 days) for tasquinimod and 133 days (range, 8 to 1,179 days)
for placebo, and most patients (82% and 92%, respectively) es-
calated to the maximum dose of 1 mg/day.
The proportion of patients with at least one dose reduction
from maximum dose was higher in the tasquinimod group than in
the placebo group (17.5% v 5.6% for the 1 mg/day dose and 1.4% v
0% for the 0.5 mg/day dose). The majority of patients in both
treatment groups experienced at least one treatment-emergent AE
(Table 3). A greater proportion of patients in the tasquinimod
group discontinued treatment because of AEs (17.7% v 10.2%),
mainly as a result of decreased appetite, fatigue, asthenia, or nausea.
Table 1. Baseline Demographic and Disease Characteristics
Characteristic
Tasquinimod
(n = 832)
Placebo
(n = 413)
No. % No. %
Median age, years
(range)
71.0 (43-92) 71.0 (48-92)
Age group (years)
# 65 214 25.7 106 25.7
66-75 371 44.6 186 45.0
76-80 144 17.3 64 15.5
. 80 103 12.4 57 13.8
Race*
White 729 87.6 359 86.9
Black 20 2.4 8 1.9
Asian 46 5.5 27 6.5
Other 37 4.4 18 4.4
Ethnicity
Hispanic/Latino 97 11.7 42 10.2
Non-Hispanic/Latino 735 88.3 371 89.8
Median time since
diagnosis,
months (range)
45.7 (0.1-299.6) 57.7 (0.3-319.9)
Karnofsky performance
status†
, 90% 187 22.5 95 23.0
$ 90% 645 77.5 318 77.0
Geographic region of
enrollment†
North America 143 17.2 72 17.4
Europe/Middle East/
Africa
505 60.7 254 61.5
Asia-Paciﬁc 94 11.3 46 11.1
Latin America 90 10.8 41 9.9
Tumor pain (VAS)‡
0 371 44.6 195 47.2
1-3 286 34.4 157 38.0
4-10 155 18.6 60 14.5
Median PSA, mg/L
(range)
54.3 (0.6-8,710.7) 50.1 (0.2-5,679.5)
Gleason score of 8 to 10
at diagnosis
398 47.8 190 46.0
Visceral disease
present†
176 21.2 87 21.1
Location of metastases
Visceral§ 161 19.4 76 18.4
Bone 824 99.0 409 99.0
Node 297 35.7 179 43.3
No. of bone metastases
, 10 377 45.3 194 47.0
$ 10 447 53.7 215 52.1
Previous second-
generation
hormonal therapy¶
65 7.8 48 11.6
Abbreviations: PSA, prostate-speciﬁc antigen; VAS, Visual Analog Scale.
*Data missing for one patient in the placebo group.
†According to interactive voice response system data, except for Europe,
Middle East, and Asia-Paciﬁc subcategories for geographic region.
‡Data missing for 20 patients in the tasquinimod group and one patient in the
placebo group.
§According to electronic case report form data. Indicated location does not
exclude other sites.
¶Abiraterone, enzalutamide, ketoconazole, or any other second-generation
hormonal treatment.
A
Median OS
Tasquinimod: 21.3 months (95% CI, 19.5 to 23.0 months)
Placebo: 24.0 months (95% CI, 21.4 to 26.9 months)
HR, 1.097 (95% CI, 0.938 to 1.282 months); P = .247
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391 344 303 273 243 225 199 176 144 89 55 27 11 2
1.0 Median rPFS
Tasquinimod: 7.0 months (95% CI, 5.8 to 8.2 months)
Placebo: 4.4 months (95% CI, 3.5 to 5.5 months)
HR, 0.639 (95% CI, 0.544 to 0.751 months); P < .001
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0 3
Placebo 181 80 45 22 15 8 3
TASQ
No. at risk
Placebo
TASQ
No. at risk
396 235 142 71 35 25 13 5 1
6 9 12 15 18 21 24 27 30
Fig 2. Kaplan-Meier analysis of (A) radiologic progression-free survival (rPFS;
central review) and (B) overall survival (OS). HR, hazard ratio; TASQ, tasquinimod.
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The most common reported AEs were GI disorders (60.2% for the
tasquinimod group v 47.9% for the placebo group), general dis-
orders and administration site conditions (55.1% v 39.9%), and
musculoskeletal and connective tissue disorders (48.2% v 36.7%).
The most frequently reported AEs are summarized in Table 3.
A total of 229 patients (27.6%) in the tasquinimod group and
97 patients (23.6%) in the placebo group experienced at least one
serious AE, the most common being renal and urinary disorders
(7.3% v 7.3%), infections and infestations (5.1% v 4.1%), and
blood and lymphatic system disorders (4.3% v 4.1%).
rPFS OS
0.5
Fav
ors
 TA
SQ
Fav
ors
 pla
ceb
o
Fav
ors
 TA
SQ
Fav
ors
 pla
ceb
o
1 1.5 2 3 4 5 0.5 1 1.5 2 3 4 5
Primary analysis ITT (n = 1,245)
No. of bone metastases < 10 (n = 483/571)*
No. of bone metastases ≥ 10 (n = 654/662)*
Visceral disease (yes) (n = 263)
Visceral disease (no) (n = 982)
Baseline VAS (0) (n = 566)
Baseline VAS (0.1-3.9) (n = 443)
Baseline VAS (4-10) (n = 215)
Karnofsky status < 90% (n = 274)
Karnofsky status ≥ 90% (n = 971)
Age 18-65 years (n = 320)
Age 66-75 years (n = 557)
Age 76-80 years (n = 208)
Age > 80 years (n = 160)
Baseline PSA ≤ median (n = 623)
Baseline PSA > median (n = 622)
Baseline Hb ≤ median (n = 643)
Baseline Hb > median (n = 602)
Baseline LDH ≤ median (n = 626)
Baseline LDH > median (n = 619)
Baseline ALP ≤ median (n = 627)
Baseline ALP > median (n = 618)
Fig 3. Radiologic progression-free survival (rPFS) and
overall survival (OS) outcomes in patient subgroups.
*Number of patients included in analyses of rPFS/OS.
ALP, alkaline phosphatase; Hb, hemoglobin; ITT, intent to
treat; LDH, lactate dehydrogenase; PSA, prostate-spe-
ciﬁc antigen; TASQ, tasquinimod; VAS, Visual Analog
Scale.
Table 2. Secondary Efﬁcacy End Points
Progression
Tasquinimod
(n = 832)
Placebo
(n = 413)
HR 95% CI PMedian (months) 95% CI Median (months) 95% CI
Radiologic progression
Local 8.0 5.8 to 8.3 4.6 3.2 to 5.5 0.683 0.591 to 0.789 , .001
Central 8.4 8.1 to 9.2 5.5 4.5 to 5.6 0.628 0.534 to 0.739 , .001
Soft tissue progression (RECIST 1.1)
Local 16.6 13.6 to 19.4 8.3 5.9 to 10.9 0.586 0.483 to 0.711 , .001
Central 16.6 14.6 to 20.5 11.1 8.2 to 14.0 0.621 0.504 to 0.765 , .001
Symptomatic progression* 9.5 7.8 to 11.1 11.9 8.9 to 14.1 1.171 1.014 to 1.353 .031
Initiation of salvage therapy† 11.4 9.1 to 13.1 8.1 6.7 to 9.7 0.778 0.667 to 0.907 .001
Initiation of further cytotoxic therapy 25.8 22.1 to 35.9 16.0 13.6 to 23.2 0.809 0.675 to 0.969 .021
Opiate use for cancer pain 29.5 25.1 to NR 35.9 29.4 to NR 1.328 1.060 to 1.664 .013
FACT-P deterioration (criterion 1)‡ 3.0 2.9 to 3.3 5.8 5.6 to 6.5 1.447 1.265 to 1.655 , .001
PSA progression 2.9 2.8 to 2.9 2.8 2.8 to 2.8 0.826 0.723 to 0.945 .003
NOTE. Time to skeletal-related events and time to symptomatic progression as a result of skeletal-related events could not be calculated because of the low number of
events.
Abbreviations: FACT-P, Functional Assessment of Cancer Therapy-Prostate; HR, hazard ratio; NR, not reached; PSA, prostate-speciﬁc antigen.
*Including death as a result of prostate cancer.
†Including radionuclide, chemotherapy, or radiation therapy.
‡Deterioration event was classiﬁed as the ﬁrst of (1) death as a result of prostate cancer, (2) signiﬁcant and meaningful decline in FACT-P total score, or (3) disease
progression, deﬁned as radiologic progression and a missing FACT-P at the same scheduled visit.
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The incidence of vascular disorders was similar for the
tasquinimod and placebo groups (12.4% v 13.1%), as was the
incidence of deep vein thrombosis (0.7% v 1.5%). Cardiac
disorders were more frequent with tasquinimod (all grades,
10% v 6.8%; grades 3 to 5, 3.4% v 1.6%; serious AEs, 3.9% v
1.9%). The frequencies of speciﬁc cardiac events for tasqui-
nimod and placebo groups, respectively, were atrial ﬁbrillation
(2.8% v 0.7%), angina pectoris (1.2% v 0.7%), cardiac failure
(1.2% v 0.2%), pericardial effusion (0.8% v 0%), pericarditis
(0.4% v 0%), coronary artery disease (0.4% v 0%), and myo-
cardial infarction (0.5% v 0.2%). The incidence of death as
a result of AEs was similar between the groups: 27 patients
(3.3%) in the tasquinimod group and 15 patients (3.6%) in the
placebo group. There were four (0.5%) cardiac AE-related
deaths in the tasquinimod group and one (0.2%) in the pla-
cebo group.
DISCUSSION
Tasquinimod was shown in a randomized phase II study to im-
prove PFS in patients with mCRPC, and it was further indicated
that this effect might be associated with an OS beneﬁt.15,16 The
primary objective of this phase III study was to conﬁrm the phase II
ﬁndings, and therefore a similar design was used with rPFS as the
primary end point. However, the study was designed with sufﬁcient
statistical power to detect a potential OS beneﬁt, and OS was the
main secondary end point. The results showed that rPFS was
signiﬁcantly delayed by tasquinimod (36% reduced risk of ra-
diographic progression or death v placebo, by central review; HR,
0.64), thereby conﬁrming the phase II ﬁndings. There was good
agreement between independent radiologists and local investigator
assessment, suggesting that rPFS can be reliably ascertained, and
recent data suggest that delays in rPFS may be associated with
prolonged survival.22
However, the signiﬁcant rPFS beneﬁt with tasquinimod did
not translate into improved survival over time. Subgroup analyses
demonstrated consistent results for rPFS and OS and did not
highlight any clear heterogeneity for an OS beneﬁt among any of
the subgroups. Tasquinimod seemed to provide clinical beneﬁt
over placebo with respect to a number of other objective radiology-
based measures as well as for time to PSA progression. Time to
initiation of further cytotoxic therapy was prolonged by 9.8 months
likely because of the delayed progression with tasquinimod
treatment. However, this was not the case for more subjective
outcomes such as time to opiate use for cancer pain, time to tumor-
related pain progression, and time to QoL deterioration, all of
which were better in the placebo group. The most common AEs
over-represented in the tasquinimod group included the types of
events that are also commonly seen as signs of cancer progression
and general health deterioration and thus may have contributed
to the unfavorable outcome of symptomatically assessed end
points.
Assessing clinical beneﬁt in mCRPC is challenging, given the
heterogeneous nature of the disease and differential effects of
subsequent therapy on traditional end points, such as OS and
postprogression time-to-event end points.23 PCWG2 guidelines on
deﬁning disease progression7 have been adopted as the standard
primary efﬁcacy measure in most recent clinical trials in mCRPC,
and there is widespread interest in the use of PCWG2-deﬁned rPFS
as a surrogate end point of survival beneﬁt. A recent analysis of the
phase III COU-AA-302 (Abiraterone Acetate in Asymptomatic or
Mildly Symptomatic Patients With Metastatic Castration-Resistant
Prostate Cancer) trial demonstrated a signiﬁcant correlation be-
tween rPFS and OS.22 However, the lack of correlation between
rPFS and OS in this study and in other phase III studies in
mCRPC24-26 illustrates that signiﬁcant improvements in rPFS may
not always translate into longer-term survival beneﬁt.
Among several possible explanations for the lack of OS beneﬁt
in this study, one contributory factor may be the availability of
more effective salvage therapies that prolong OS treatment after the
study,27 many of which were not widely available at the time of the
phase II study. The current availability of such agents (eg, abir-
aterone and enzalutamide) may have had an impact on the course
of disease because patients in the placebo group gained access
before those in the tasquinimod group on account of their earlier
withdrawal from study treatment. Indeed, post-treatment use of
abiraterone and enzalutamide was more common among patients
in the placebo group. Furthermore, baseline characteristics suggest
a more aggressive cancer population in the tasquinimod arm as
indicated by an imbalance in median time since diagnosis and
baseline Visual Analog Scale score for tumor-related pain. It may
also be that the survival results were inﬂuenced by a combination
of the relatively modest effect on rPFS and other confounding
factors, suggesting that tasquinimod may not have sufﬁcient ef-
ﬁcacy as a single agent to have an impact on long-term OS.
Further study of predictive biomarkers of tasquinimod efﬁ-
cacy may be warranted to determine whether certain subgroups
will derive an OS advantage. Data from the phase II trial suggested
that men with low baseline thrombospondin-1 levels derived
the greatest beneﬁt from tasquinimod.16 Because tasquinimod is
Table 3. Most Common AEs Occurring in at Least 5% of Patients in Either
Treatment Group
AE
Tasquinimod
(n = 830)
Placebo
(n = 411)
All Grades
Grades
3 to 5 All Grades
Grades
3 to 5
No. % No. % No. % No. %
All AEs 791 95.3 355 42.8 381 92.7 138 33.6
Cancer pain 264 31.8 27 3.3 129 31.4 10 2.4
Decreased appetite 250 30.1 15 1.8 67 16.3 4 1.0
Nausea 222 26.7 7 0.8 89 21.7 3 0.7
Fatigue 217 26.1 28 3.4 72 17.5 9 2.2
Constipation 194 23.4 8 1.0 67 16.3 2 0.5
Anemia 179 21.6 69 8.3 67 16.3 31 7.5
Asthenia 140 16.9 23 2.8 51 12.4 8 1.9
Decreased weight 125 15.1 15 1.8 35 8.5 3 0.7
Back pain 105 12.7 10 1.2 38 9.2 1 0.2
Pain in extremity 104 12.5 10 1.2 31 7.5 1 0.2
Arthralgia 101 12.2 8 1.0 52 12.7 0
Diarrhea 94 11.3 3 0.4 42 10.2 3 0.7
Insomnia 87 10.5 2 0.2 30 7.3 0
Vomiting 87 10.5 3 0.4 28 6.8 3 0.7
Peripheral edema 85 10.2 3 0.4 28 6.8 1 0.2
Abbreviation: AE, adverse event.
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known to increase this antiangiogenic marker in preclinical tumor
models,28 there may be a mechanistic basis for further examination
of predictive biomarkers identiﬁed in this study. Preclinical evi-
dence also suggests that tasquinimod has immunomodulatory
activity, shown as an inhibitory effect on myeloid-derived sup-
pressive cells and M2-polarized tumor-associated macrophages.13
Identiﬁcation of a potential immunologic biomarker will help with
patient selection and determination of the most rational combi-
nation strategy for developing S100A9 inhibitors.
The tolerability of tasquinimod was good overall, and the vast
majority of patients were able to escalate to the maximum 1-mg/day
dose according to the predeﬁned schedule. Dose interruptions
or reductions were infrequent, and the overall safety proﬁle was
consistent with that observed in the phase II study. Tasquinimod
was associated with a higher rate of withdrawals as a result of AEs.
GI and musculoskeletal disorders occurred at a slightly higher
frequency with tasquinimod, as seen in the phase II study. The
overall incidence of cardiovascular events was low but, as observed
previously,15,16 was slightly higher with tasquinimod. This higher
rate of cardiovascular events may have contributed to the lack of
survival beneﬁt due to early drug discontinuation. However,
treatment-related deaths were not increased with tasquinimod,
suggesting lack of efﬁcacy rather than toxicity as the main con-
tributing factor.
In conclusion, this phase III study conﬁrmed that tasquini-
mod improved rPFS in patients with mCRPC compared with
placebo. This beneﬁt did not translate into an improvement in OS.
The tolerability proﬁle of tasquinimod was consistent with that in
previous studies. On the basis of the lack of OS beneﬁt observed in
this study, further clinical development of tasquinimod in this
patient population was not pursued.
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Appendix
Table A1. Phase III Study Sites (241) in 37 Countries
Site Principal Investigator
Australia
The Tweed Hospital, Tweed Heads Ehtesham Abdi, MBBS
Coffs Harbor Health Campus, Coffs Harbor Karen Briscoe, MBBS
Australian Prostate Cancer Research Centre, Richmond Anthony Costello, MD, MBBS
St John of God Subiaco Hospital, Subiaco Siobhan Ng, MBBS
St Vincent’s Hospital, Darlinghurst Richard Epstein, MD, PhD, MBBS
Royal Prince Alfred Hospital, Camperdown Lisa Horvath, MBBS, PhD
India
Jehangir Clinical Development Centre, Pune Bhalchandra Kashyapi, MBBS, MCh, MS
New Zealand
Tauranga Urology Research, Tauranga Peter Gilling, MD
Canterbury Urology Research Trust, Christchurch Frank Kueppers, MD, PhD
Roundhay Medical Centre and Nelson Public Hospital, Nelson; Wairau Public
Hospital, Blenheim
Patrick Meffan, MBChB, FRACS
Palmerston North Hospital, Palmerston North Quinten King, MBBCh, FRCS
Korea
Gangnam Severance Hospital, Seoul Byung Ha Chung, MD, PhD
Chonnam National University Hospital, Gwangju Taek Won Kang, MD, PhD
Seoul St Mary’s Hospital, Seoul Sae Woong Kim, MD, PhD
Asan Medical Center, Seoul Choung-Soo Kim, MD
Severance Hospital, Seoul Sung Joon Hong, MD, PhD, MS
Samsung Medical Center, Seoul Hyun Moo Lee, MD, PhD
Taiwan
Chang Gung Medical Foundation, Taoyuan Cheng-Keng Chuang, MD
Taichung Veterans General Hospital, Taichung Yen-Chuan Ou, MD, PhD
National Taiwan University Hospital, Taipei Yu-Chieh Tsai, MD
Kaohsiung Veterans General Hospital, Kaohsiung Tong-Lin Wu, MD, EMBA
China
Urology Surgery Department, Beijing Lijun Chen, MD
Fudan University Shanghai Cancer Center, Shanghai Dingwei Ye, MD
Chengdu Military General Hospital, Chengdu Liang Wang, MD
Urology Surgery Department, Shantou Junhong Zheng, MD
Huashan Hospital, Shanghai Qiang Ding, MD
Zhongnan Hospital of Wuhan University, Wuhan Fuxiang Zhou, MD
Argentina
Centro Oncolo´gico “A´gave,” Santa Fe Natalia Broglia Sicco, MD
Centro de Diagno´stico Urolo´gico, Buenos Aires Luis Fernando Montes de Oca, MD
Centro Oncolo´gico Fundacion Koria, St Rosa Pablo Picon, MD
Hospital Italiano de Buenos Aires, Buenos Aires Marı´a Pallotta, MD
Brazil
Hospital Evangelico de Cachoeiro de Itapemirim, Cachoeiro de Itapemirim Sabina Aleixo, MD
Granbery Juiz de Fora Hospital Universitario da Universidade Federal de Juiz
de Fora Avenue Eugenio do Nascimento, Juiz de Fora
Christiane Alves, MD
Rio de Janeiro Hospital St Maria Madalena Estrada do Dende, Rio de Janeiro Iane Cardoso, MD
Natal Liga Norte Riograndense Contra o Cancer Unidade I Hospital Luiz
Antonio, Natal
Danielli Matias, MD
Florianopolis Hospital, Bala Sul Medical Center, Florianopolis Yeni Neron, MD
Salvador Hospital da Bahia, Salvador Jose´ Nogueira, MD
Sao Paulo Centro de Pesquisa Clinical, Sao Paulo Roberto Rocha, MD
Centro Oncologico Mogi das Cruzez, Sao Paulo Daniel Grabarz, MD
Passo Fundo Hospital Sao Vicente de Paulo, Passo Fundo Luis Schlittler, MD
Hospital de Clinicas de Porto Alegre, Porto Alegre Gilberto Schwartsmann, MD
Rio Sul Centro de Atencao e Saude Humana, Rio de Janeiro Hospital, Rio de
Janeiro
Leonardo Osorio, MD; Heloisa M. Resende, MD
Universidade Estadual Paulista, Sao Paulo Guareide Carelli, MD
Liga Paranaense de Combate ao Cancer, Hospital Erasto Gaertner, Curitba Flavio Tomasich, MD
(continued on following page)
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Table A1. Phase III Study Sites (241) in 37 Countries (continued)
Site Principal Investigator
Chile
Hospital Clinico Vina de Mar Limache, Vina de Mar Alejandro Acevedo Gaete, MD
Clinicia Alemana de Temuco, Temuco Mario Gorena, MD
Uromed Ave Salvador 351, Santiago Anibal Salazar Huerta, MD
Hospital Dipreca, Santiago Luis Soto Diaz, MD
Hospital de Carabineros General Humberto Arriagada Valdivieso, Santiago Nelson Orellana Salinas, MD
Colombia
Fundacion Clinica Valle del Lili, Cali Manuel Duque Galan, MD
Fundacion St Fe de Bogota, Bogota Carlos Vargas, MD
Mexico
Hospital Angeles Puebla, Puebla Jose´ Arroyo Kuribreña, MD
Hospital Aranda de la Parra, Guanajuato Marco Badillo Santoyo, MD
Christus Muguerza del Parque, Chihuahua Roberto Hidalgo-Silva, MD
Hospital Angeles Culiacan, Culiacan Gustavo Gaxiola Meza, MD
Consultorio Medico, Zapopan Jose Rodriguez Rivera, MD
Panama
Centro Hemato Oncologico Paitilla Consultorios Medicos Royal Center,
Panama City
Juan Bares Weeden, MD
Clinica Hospital San Fernando Centro Especializado, Panama City Javier Del Rosario Gibbs, MD
Medical Research Center Ediﬁcio Consultotios America, Panama City Roberto Lopez Sanchez, MD
Clinica Hospital San Fernando, Panama City Alejandro Manduley, MD
Peru
Instituto Re´gional de Enfermedades Neoplasicas del Sur Ave de la Salud
Arequipa, Arequipa
Ernesto Vargas Quezada, MD
Hospital Nacional Carlos Alberto Seguin Escobedo Calle Peral y Ayacucho,
Arequipa
Hernan Moron Escobar, MD
Belgium
Centre Hospitalier Universitaire Sart Tilman, Liege Brieuc Sautois, MD
Algemeen Ziekenhuis Groeninge Burgemeester, Kortijk Patrick Werbrouck, MD
Erasme Hospital, Universite´ Libre de Bruxelles, Brussels Thierry Roumegue`re, MD
Algemeen Ziekenhuis Maria Middelares, Gent Filip Ameye, MD
Bulgaria
Hospital for Treatment of Oncology Disease, Soﬁa Borislav Dimitrov, MD
Oncology Center Plovdiv, Plovdiv Petar Petrov, MD
Hospital Oncology Disease Medical Oncotherapy and Palliative Care Base II,
Varna
Violina Taskova, MD
University Multiproﬁle Hospital Chemotherapy Department, Pleven Rumyana Micheva, MD
Czech Republic
Fakultni Nemocnice v Motole, Urology Clinic, Prague Josef Stolz, MD
Urocentrum Praha, Prague Michaela Matouskova, MD
Krajska Zdravotni – Masarykova Nemocnice, Clinic of Urology and Robotic
Surgery, Usti nad Labem
Jan Schraml, MD
Nemocnice Novy Jicin, Urology Department, Novy Jicin Miroslav Stursa, MD
Fakultni Nemocnice Olomouc, Urology Clinic, Olomouc Vladimir Student, MD
Estonia
Tartu University Hospital, Tartu Jaanus Kahu, MD
France
Central Hospital Cannes, Cannes Regis Kaphan, MD
Beau Soleil Clinic, Montpellier Xavier Rebillard, MD
Foch Hospital, Suresnes Christine Theodore, MD
Regional Center de Lutte, Angers Re´my Delva, MD
Centre Hospital Lyon-Sud, Pierre-Benite Alain Rufﬁon, MD
Centre Re´gional de Lutte Contre le Cancer Val d’Aurelle, Montpellier David Azria, MD
Centre Hospitalier Universitaire Rennes Hospital Pontchaillou, Rennes Sebastien Vincendeau, MD
Curie Institute, Paris Philippe Beuzeboc, MD
Hopital Saint-Louis Service d’Oncologie, Paris Ste´phane Culine, MD
Centre Hospitalier Universitaire La Timone Adultes-Service d’Oncologie
Medicale, Marseille
Jean-Laurent Deville, MD
Germany
Eberhard-Karls University Tu¨bingen, Clinic for Urology, Tu¨bingen Arnulf Stenzl, MD
Urologic Study Ofﬁce, Nurtingen Susan Feyerabend, MD
University Hospital Mu¨nster, Urology, Mu¨nster Martin Bo¨gemann, MD
Hospitals Nordoberpfalz, Urology, Weiden Theodor Klotz, MD
University Hospital Gießen and Marburg, Clinic for Urology and Pediatric
Urology, Marburg
Alex Hegele, MD
University Hospital Cologne, Clinic for Urology, Cologne Sebastian Wille, MD
University Hospital Munich, Clinic for Urology, Munich Phillip Nuhn, MD; Claudius Fu¨llhase, MD; Patrick Bastian, MD
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Table A1. Phase III Study Sites (241) in 37 Countries (continued)
Site Principal Investigator
University Hospital Carl Gustav Carus Dresden, Dresden Manfred Wirth, MD
Martini-Clinic at the University Hospital Hamburg-Eppendorf, Hamburg Thomas Steuber, MD, PD
University Hospital Mannheim, Clinic for Urology, Mannheim Christian Bolenz, MD, PD
Greece
Alexandra Hospital Department of Clinical Therapeutics, Athens Eleni Efstathiou, MD, PhD
Athens Oncology Hospital Urology Clinic, Athens Anastasios Thanos, MD
Thessaloniki General Hospital, Thessaloniki Athanassios Papathanasiou, MD
Patras University General Hospital, Rion Patras Petros Perimenis, MD
Israel
Oncology Institute, The Chaim Sheba Medical Center, Tel Hashomer Raanan Berger, MD, PhD
The Lady Davis Carmel Medical Center, Haifa Avi Stein, MD
Assaf Harofe Medical Center Oncology Department, Zeriﬁn Avishay Sella, MD
Tel Aviv Sourasky Medical Center, Oncology Department, Tel Aviv Eliahu Gez, MD
Oncology Institute Rambam Health Care Campus, Haifa Avivit Peer, MD
Institute of Oncology Davidoff Cancer Center, Rabin Medical Center, Tikva Eli Rosenbaum, MD
Bnai Zion Medical Center, Haifa Ofer Nativ, MD
Sharett Institute of Oncology, Hadassah University Hospital, Jerusalem Stephen Frank, MD
Soroka University Medical Center, Be’er Sheva Wilmosh Mermershtain, MD
Italy
San Camillo Forlanini Hospital, Rome Cora Sternberg, MD
Scientiﬁc Institute Romangnolo Via Piero Maroncelli, Meldola Cecilia Menna, MD
Oncology Institute Veneto, Padova Umberto Basso, MD
Hospital di Lecco, Lecco Antonio Ardizzoia, MD
Oncologia Falck Hospital, Niguarda Ca Granda Piazzale Hospital, Milan Salvatore Siena, MD
Azienda Ospedaliero Universitaria Giovanni Battista di TorinoMolinette, Turin Libero Ciuffreda, MD
Institute di Cremona, Cremona Rodolfo Passalacqua, MD
Ospedale degli Infermi di Faenza Unita` di Oncologia di Oncologia Medica,
Faenza
Francesco Carrozza, MD; Giorgio Cruciani, MD
Hospital San Carlo Borromeo, Milan Maria Locatelli, MD
Latvia
Riga Eastern Clinical University Hospital, Latvian Oncology Center, Riga Arija Brize, MD
Private practice of Dzintra Litavniece, Liepaja Dzintra Litavniece, MD
P. Stradins Clinical University Hospital, Riga Egils Vjaters, MD
Lebanon
Middle East Institute of Health, Bsalim El Meten Abi Gerges Dany, MD
American University of Beirut Medical Center, Beirut Ali Shamseddine, MD
Lithuania
Vilnius University Hospital, Vilnius Feliksas Jankevicius, MD
Institute of Oncology Vilnius University, Vilnius Albertas Ulys, MD, PhD
Lithuanian University Health Sciences Kaunas Clinics, Kaunas Daimantas Milonas, MD
The Netherlands
St Elizabeth Hospital, Tilburg P. Kil, MD, PhD
Martini Ziekenhuis, Groningen L.F.A. Wymenga, MD, PhD
Canisius Wilhelmina Hospital, Nijmegen H. Vergunst, MD
Leiden University Medical Center, Leiden A.J. Gelderblom, MD
Vrije Universiteit Medical Center, Amsterdam R.J.A. van Moorselaar, MD
University Medical Center St Radboud, Nijmegen P.F.A. Mulders, MD
Poland
Curie Oncology Institute, Nowotworow Oncology Clinic, Warsaw Tomasz Demkow, MD, PhD
Niepubliczny Zaklad Opieki Zdrowotnej Urology Center, Myslowice Adam Dobrowolski, MD
Regional Osrodek Oncology, Lodz Ewa Kalinka-Warzocha, MD
EuroMediCare, Wroclaw Rafal Kmieciak, MD
Wojewodki Hospital Urology Clinic, Bialystok Robert Kozlowski, MD, PhD
Wielkopoiskie Oncology Center, Poznan Piotr Milecki, MD, PhD
LexMedica Rudolfa, Wroclaw Zenona Jablonska, MD
Romania
Oncolab, Craiova Dan Lungulescu, MD
Fundeni Clinical Institute, Bucharest Mihai Harza, MD
Sf loan cel Nou Emergency County Hospital, Suceava Doina Ganea, MD, PhD
The Oncology Institute, Cluj Napoca Cristina Cebotaru, MD; Tudor Ciuleanu, MD, PhD
Opris Emergency County Hospital, Baia Mare Dumitru Filip, MD
Oncomed SRL, Timisoara Cristina Oprean, MD
Ianuli Medical Consult SRL, Bucharest Carmen Ianuli, MD
Municipal Hospital Ploiesti, Ploiesti Gabriel Doru Ghizdavescu, MD
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Table A1. Phase III Study Sites (241) in 37 Countries (continued)
Site Principal Investigator
Russia
Omsk Healthcare, Oncology Center, Omsk Evgeniy Kopyltsov, MD, PhD
Clinic Andros Lenina Street, St Petersburg Alexey Plekhanov, MD, PhD
Leningrad Regional Oncology Center, St Petersburg Denis Khvorostenko, MD
St Petersburg Healthcare City Hospital, St Petersburg Vakhtang Shanava, MD, PhD
Vladimir Healthcare Oncology Center, Vladimir Natalya Rodicheva, MD
Orkli, Sredniy Prospekt, St Petersburg Vladimir Kheifets, MD, PhD
Federal State Institution Moscow Research Oncology Institute, Moscow Boris Alekseev, MD, PhD
State Institution of Healthcare Sverdlovsk Regional Hospital, Ekaterinburg Alexander Zyryanov, MD
Regional State Institution of Healthcare Novosibirsk Regional Oncology
Centre, Novosibirsk
Marat Zaripov, MD
Slovak Republic
Ambulatory Urology Clinic, Trecin Roman Sokol, MD
Cuimed, Bratislava Frederico Goncalves, MD, PhD
Spain
Hospital Clinic 1 Provincial Oncology Servico deOncologiaMedica, Barcelona Begoña Mellado, MD
Corporacio Sanitaria Parc Tauli Hospital de Sabadell Servicio de Oncologia
Medica, Barcelona
Enrique Gallardo, MD
Hospital Infanta Soﬁa, Madrid Emilio Rı´os, MD
Clinica Universidad de Navarra Servicio de Oncologia, Pamplona Jose Luis Perez Gracia, MD
Hospital Universitario Virgen del Rocio Servicio de Oncologia Medica Ave
Manuel Siurot, Sevilla
Begoña Pe´rez Valderrama, MD
Hospital Clinico Universitario de Valencia Servicio de Oncologia Medica,
Valencia
Isabel Chirivella, MD
Hospital Universitario Marques de Valdecilla Servicio de Oncologia Medica,
Santander
Marta Lopez-Brea Piqueras, MD
Hospital Universitario Vall D’Hebron Servicio de Oncologia-Unidad, Barcelona Joan Carles Galceran, MD
Hospital de la Santa Creu, Barcelona Jose´ Pablo Maroto, MD
Hospital Universitario Fundacion Alcorcon Servicio de Oncologia Medica,
Alcorcon
Susana Hernando Polo Jesus, MD; Garcia-Donas Jimenez, MD
Hospital Clinico Universitario “Lozano Blesa” Servicio de Oncologia Medica,
Zaragoza
Alberto Saenz Cusi, MD
Hospital Universitario Central de Asturias Servicio de Oncologia, Oviedo Emilio Esteban Gonzalez, MD; Enrique Estrada, MD
Instituto Valenciano de Oncologia, Valencia Eduardo Solsona Narbon, MD
Sweden
Radiumhemmet Karolinska University Hospital, Stockholm Sten Nilsson, MD
Sahlgrenska University Hospital, Gothenburg Jan-Erik Damber, MD
Central Hospital Karlstad Oncology Clinic, Karlstad Claes Ginman, MD
Turkey
Istanbul University Cerrahpasa School of Medicine, Istanbul Can Obek, MD
Ukraine
Municipal Institution of Healthcare VI Shapoval Regional Clinical Centre of
Urology and Nephrology Urology Department #4, Kharkiv
Igor Antonyan, MD, PhD
Ivano-Frankivsk Regional Oncology, Dispensary Clinical Mammology Centre,
Department with Urology Beds Ivano-Frankivsk
Volodymyr Romanchuk, MD; Ipolit Kostinskyy, Professor,
MD, PhD
Municipal Institution, Multiﬁeld City Clinical Hospital #4, Department of
Chemotherapy, Dnipropetrovsk
Igor Bondarenko, Professor, MD, PhD
Municipal Institution, Zaporizhzhia Regional Clinical Hospital of Zaporizhzhia
Regional Council, Urology Department; State Institution Zaporizhzhia
Medical Academy of Postgraduate Education of Ministry of Health of
Ukraine Chair of Urology, Zaporizhzhya
Olexiy Lyulko, Professor, MD
Kyiv City Clinical Hospital #3 Urology Department, Kyiv Petro Ivashchenko, MD
Municipal Institution, Dnipropetrovsk Regional Clinical Hospital named after
I.I. Mechnikov, Urology Department #2, Dnipropetrovsk State Medical
Academy Chair of Urology, Operative Surgery and Topographic Anatomy,
Dnipropetrovsk
Olexiy Lyulko, Professor, MD; Viktor Stus, Professor, MD
Regional Municipal Institution, Chernivtsi Regional Clinical Hospital,
Chemivtsi
Valerii Zaitsev, Professor, MD
Kyiv Oleksandrivska Clinical Hospital, Urology Department #3, Kyiv Sergii Pasiechnikov, Professor, MD
Uzhgorod Central City Clinical Hospital, City Oncology Centre, Uzhgorod Yevhen Hotko, MSD, MD, PhD
Municipal Clinical Medical and Preventive Treatment Institution, Donetsk
Regional Antitumour Centre, Donetsk
Andriy Anishchenko, MD
Medical and Preventive Treatment Institution, Volyn Regional Oncology
Dispensary, Lutsk
Orest Andrusenko, MD
Lviv State Oncology Regional Treatment and Diagnostic Center, Lviv Yaroslav Shparyk, MD, PhD
Municipal Treatment-Prophylactic, Institution Central City Clinical Hospital,
Donetsk
Yuri Semyak, MD
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Table A1. Phase III Study Sites (241) in 37 Countries (continued)
Site Principal Investigator
Municipal Institution of Kyiv Regional Council, Kyiv Regional Oncology
Dispensary, Kyiv
Iurii Golovko, MD
Center of Reconstructive and Restorative Medicine (University Clinic) of
Odesa National Medical University, Odesa
Nataliia Tavartkiladze, MD
United Kingdom
St James University Hospital, Leeds William Cross, MD
Royal Marsden Hospital, Sutton Robert Huddart, MD
Mount Vernon Hospital, Northwood Peter Hoskin, MD
Oxford Cancer Centre, Headington Andrew Protheroe, MD
St Richard’s Hospital, Chichester James Hicks, MD; Paul Carter, MD
Scunthorpe General Hospital, Scunthorpe Sanjay Dixit, MD
Sarah Cannon Research, London Simon Chowdhury, MA, MBBS, MRCP, PhD
University Hospitals Birmingham National Health Service Foundation Trust
Queen Elizabeth Hospital, Birmingham
Nicholas James, MD
Nottingham University Hospitals National Health Service Trust, Nottingham Santhanam Sundar, MD
Canada
The Fe/Male Health Centre, Oakville, ON Richard Casey, MD
Probity Medical Research, North York, ON Stanley Flax, MB, BCh
Southern Interior Medical Research, Kelowna, BC Thomas Kinahan, MD
Mor Urology, Newmarket, ON Morrie Liquornik, MD
Paciﬁc Urologic Research, Victoria, BC Gary Steinhoff, MD
St Joseph’s Lifecare Centre, Brantford, ON Wilson Leung, MD
United States
Duke University Medical Center, Durham, NC Andrew Armstrong, MD
Peachtree Hematology-Oncology Consultants, Atlanta, GA Vasileios John Assikis, MD
Urologic Consultants of Pennsylvania, Bala Cynwyd, PA Laurence H. Belkoff, DO
Paciﬁc Urology Institute, Santa Monica, CA Stanley Brosman, MD
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
University, Baltimore, MD
Michael Carducci, MD
Ventura County Hematology Oncology Specialists, Oxnard, CA Kevin Q. Chang, MD
Vanderbilt University Medical Center, Nashville, TN Sam Chang, MD
Clinical Trials Ofﬁce, Dallas, TX James Cochran, MD
University of Pittsburgh Physicians Department of Urology, Pittsburgh, PA Jeffrey Gingrich, MD
Premier Medical Group, Poughkeepsie, NY Evan R. Goldﬁscher, MD
Midwest Urology Associates, Melrose Park, IL Richard G. Harris, MD
Lawrenceville Urology, Lawrenceville, NJ Gary S. Karlin, MD
Capitol Comprehensive Cancer Care Clinic, Jefferson City, MO Ali Khojasteh, MD
Carolina Urology Partners, Concord, NC David U. Lipsitz, MD, FACS, CPI
Palm Beach Urology Associates, Wellington, FL Georgis Patsias, MD
Roswell Park Cancer Center Institute, Buffalo, NY Roberto Pili, MD
Grand Strand Urology, Myrtle Beach, SC Neal Shore, MD, FACS
Lancaster Urology, Lancaster, PA Paul R. Sieber, MD
Boise Urology, Meridian, ID Joseph H. Williams, MD
Metropolitan Urology, Jeffersonville, IN James L. Bailen, MD
Frankel, Reed & Evans, Burien, WA Jeffrey M. Frankel, MD
Virginia Oncology Associates, Norfolk, VA Mark T. Fleming, MD
Virginia Cancer Specialists, Fairfax, VA Alexander I. Spira, MD
Texas Oncology-Baylor Charles A. Sammons Cancer Center, Dallas, TX Thomas E. Hutson, DO
Blue Ridge Cancer Care, Roanoke, VA Mark D. Kochenderfer, MD
Willamette Valley Cancer Institute and Research Center, Eugene, OR Joseph A. Fiorillo, MD; John R. Caton Jr, MD
Comprehensive Cancer Centers of Nevada, Las Vegas, NV Nicholas J. Vogelzang, MD
Raleigh Hematology Oncology Associates, DBA Cancer Centers of North
Carolina, Raleigh, NC
William R. Berry, MD
University of Utah/Huntsman Cancer Center, Salt Lake City, UT Neeraj Agarwal, MD
Associates in Oncology/Hematology, Rockville, MD Manish Agrawal, MD
Oncology Specialists, Park Ridge, IL Timothy Lestingi, MD; Chadi Nabhan, MD
John Theurer Cancer Center at Hackensack, Hackensack, NJ Robert Alter, MD
Redwood Regional Medical Group, Santa Rosa, CA Wes S. Lee, MD
Arizona Oncology Associates, Tucson, AZ Christopher Di Simone, MD
Tufts Medical Center, Boston, MA Paul Mathew, MD
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Table A2. Other Secondary Efﬁcacy End Points
Outcomes
Tasquinimod
(n = 832)
Placebo
(n = 413)
HR 95% CI PMedian (months) 95% CI Median (months) 95% CI
New bone lesion
Local 8.3 6.0 to 9.5 4.5 3.1 to 5.6 0.723 0.616 to 0.848 , .001
Central 8.1 6.0 to 8.5 4.8 3.1 to 5.6 0.735 0.623 to 0.867 , .001
New soft tissue lesion
Local 19.4 16.6 to 25.3 11.1 8.6 to 16.4 0.612 0.493 to 0.760 , .001
Central 20.5 19.3 to NR 19.1 11.5 to NR 0.678 0.531 to 0.866 .002
First radiologic or symptomatic progression
Local 4.8 4.1 to 5.5 3.2 2.9 to 4.2 0.812 0.714 to 0.925 .002
Central 5.2 4.4 to 5.6 3.7 3.1 to 4.4 0.849 0.745 to 0.967 .013
First radiologic or symptomatic progression or death
Local 4.8 4.0 to 5.5 3.2 2.9 to 4.1 0.812 .716 to .922 .001
Central 5.2 4.4 to 5.6 3.6 3.1 to 4.3 0.845 0.744 to 0.959 .009
Tumor-related pain progression* 5.6 4.9 to 6.0 8.3 6.7 to 10.8 1.259 1.097 to 1.445 , .001
KPS deterioration 11.7 10.3 to 13.6 17.4 14.5 to 19.1 1.292 1.110 to 1.505 , .001
PSA doubling time 5.2 4.5 to 5.6 3.3 2.9 to 4.0 0.734 0.631 to 0.853 , .001
Abbreviations: HR, hazard ratio; KPS, Karnofsky performance status; NR, not reached; PSA, prostate-speciﬁc antigen.
*Including palliative interventions.
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